Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

被引:25
作者
Illi, Ari [1 ,2 ]
Poutanen, Outi [2 ]
Setala-Soikkeli, Eija [4 ]
Kampman, Olli [5 ,7 ]
Viikki, Merja
Huhtala, Heini [6 ]
Mononen, Nina [3 ]
Haraldsson, Susann [8 ]
Koivisto, Pasi A. [8 ,9 ]
Leinonen, Esa [2 ]
Lehtimaki, Terho [1 ,3 ]
机构
[1] Univ Tampere, Sch Med, Dept Clin Chem, Tampere 33014, Finland
[2] Tampere Univ Hosp, Dept Psychiat, Tampere, Finland
[3] Tampere Univ Hosp, Ctr Lab Med, Tampere, Finland
[4] Kanta Hame Cent Hosp, Dept Psychiat, Hameenlinna, Finland
[5] Seinajoki Hosp Dist, Dept Psychiat, Seinajoki, Finland
[6] Univ Tampere, Sch Publ Hlth, Tampere 33014, Finland
[7] Dept Psychiat, Lahti, Finland
[8] Umea Univ, Dept Med Biosci, Div Med & Clin Genet, Umea, Sweden
[9] Tampere Univ Hosp, Mol Genet Lab, Tampere, Finland
关键词
Serotonin transporter; 5-HTTLPR; MDD; SSRI; Drug response; GENE PROMOTER POLYMORPHISM; TRANSPORTER GENE; ANTIDEPRESSANT RESPONSE; EFFICACY; ASSOCIATION; PAROXETINE; DEPRESSION; FLUOXETINE; SERTRALINE; RECEPTOR;
D O I
10.1007/s00406-010-0126-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The role of a functional polymorphism in the transcriptional control region of serotonin transporter gene (5-HTTLPR, SERTPR) has been studied intensively in major depression and in the response to selective serotonin inhibitors (SSRIs) in major depression. The findings have been contradictory, although majority of the studies indicate that the short allele is associated with poor response to SSRIs in major depression. In the present study, we evaluated the association of 5-HTTLPR with treatment response to SSRI medication in Finnish Caucasian MDD patients. A secondary purpose was to study the possible association of this particular polymorphism with major depressive disorder. The aim of the study was to replicate the previous findings in this area. Primary outcomes of the treatment were remission, defined by an exit score of seven or less, and response, defined by a reduction of at least 50% on the MADRS. We had also a control population of 375 healthy blood donors, as a secondary objective was to evaluate the possible association of this particular polymorphism with major depressive disorder. Twenty-nine of the 85 (34.1%) patients reached the remission and 58.8% achieved the predefined response criteria. The l/l genotype of 5-HTTLPR was presented in 51.7% of those patients who achieved remission vs. 25.0% in the non-remitters (P = 0.03). The result remained statistically significant after adjusting for age, gender, medication and MADRS points at the study entry. However, the small sample size limits the reliability of this result.
引用
收藏
页码:95 / 102
页数:8
相关论文
共 27 条
[1]   5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study [J].
Arias, B ;
Catalán, R ;
Gastó, C ;
Gutiérrez, B ;
Fañanás, L .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (06) :563-567
[2]   Association study designs for complex diseases [J].
Cardon, LR ;
Bell, JI .
NATURE REVIEWS GENETICS, 2001, 2 (02) :91-99
[3]   The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder [J].
Durham, LK ;
Webb, SM ;
Milos, PM ;
Clary, CM ;
Seymour, AB .
PSYCHOPHARMACOLOGY, 2004, 174 (04) :525-529
[4]   Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder [J].
Hong, CJ ;
Chen, TJ ;
Yu, YWY ;
Tsai, SJ .
PHARMACOGENOMICS JOURNAL, 2006, 6 (01) :27-33
[5]   Moderation of antidepressant response by the serotonin transporter gene [J].
Huezo-Diaz, Patricia ;
Uher, Rudolf ;
Smith, Rebecca ;
Rietschel, Marcella ;
Henigsberg, Neven ;
Marusic, Andrej ;
Mors, Ole ;
Maier, Wolfgang ;
Hauser, Joanna ;
Souery, Daniel ;
Placentino, Anna ;
Zobel, Astrid ;
Larsen, Erik Roj ;
Czerski, Piotr M. ;
Gupta, Bhanu ;
Hoda, Farzana ;
Perroud, Nader ;
Farmer, Anne ;
Craig, Ian ;
Aitchison, Katherine J. ;
McGuffin, Peter .
BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 (01) :30-38
[6]   Age-dependent antidepressant pharmacogenomics:: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline [J].
Joyce, PR ;
Mulder, RT ;
Luty, SE ;
McKenzie, JM ;
Miller, AL ;
Rogers, GR ;
Kennedy, MA .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04) :339-346
[7]   Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients [J].
Kato, Masaki ;
Fukuda, Tsuyoshi ;
Wakeno, Masataka ;
Fukuda, Kazuhiro ;
Okugawa, Gaku ;
Ikenaga, Yuka ;
Yamashita, Megumi ;
Takekita, Yoshiteru ;
Nobuhara, Kenji ;
Azuma, Junichi ;
Kinoshita, Toshihiko .
NEUROPSYCHOBIOLOGY, 2006, 53 (04) :186-195
[8]   Serotonin transporter gene polymorphism and antidepressant response [J].
Kim, DK ;
Lim, SW ;
Lee, S ;
Sohn, SE ;
Kim, S ;
Hahn, CG ;
Carroll, BJ .
NEUROREPORT, 2000, 11 (01) :215-219
[9]   Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression [J].
Kim, Hyeran ;
Lim, Shinn-Won ;
Kim, Seonwoo ;
Kim, Jong-Won ;
Chang, Yun Hee ;
Carroll, Bernard J. ;
Kim, Doh Kwan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (13) :1609-1618
[10]   Sequence analysis of the serotonin transporter and associations with antidepressant response [J].
Kraft, JB ;
Slager, SL ;
McGrath, PJ ;
Hamilton, SP .
BIOLOGICAL PSYCHIATRY, 2005, 58 (05) :374-381